AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
13:23
Alexandru Nazare is participating on Monday in the ECOFIN and Eurogroup meetings in Brussels
13:07
Riyadh, Saudi Arabia, targeted by missiles / An Aramco building was damaged in the financial district
12:43
Zaporizhzhia nuclear power plant has been left without external power / Diesel generators maintain reactor cooling
12:33
Romania may maintain until the end of 2029 the 50% limit on VAT deductions for company cars used for both business and personal purposes
12:23
ELCEN additionally supplies 1,860 tons of hot water per hour to cover losses in the Termoenergetica network
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
